#United States #Philadelphia #Signant Health #eCOA #Ametris

Signant Health's Strategic Acquisition of Ametris

On May 14, 2026, Signant Health, a pioneer in evidence generation for clinical trials, announced its acquisition of Ametris (previously known as ActiGraph), marking a significant stride in enhancing digital health solutions. With a focus on creating a robust end-to-end platform for electronic Clinical Outcome Assessments (eCOA) and validated digital outcome measures, this strategic move is poised to reshape the landscape of clinical research.

The Rationale Behind the Acquisition

In the ever-evolving realm of clinical trials, the importance of integrating patient perspectives with objective data cannot be overstated. Clinical trial sponsors are continually seeking multiple lines of evidence to substantiate treatment benefits effectively. To achieve this, they often grapple with managing various vendors and datasets, leading to complexities in operations and integration. By acquiring Ametris, Signant aims to consolidate these processes, providing a unified solution that simplifies multimodal study management. This strategic acquisition will allow sponsors to work with a single provider, effectively mitigating the challenges presented by a fragmented vendor landscape.

Roger Smith, CEO of Signant, emphasized the significance of this acquisition, stating, "This acquisition represents our commitment to advancing what's possible in clinical evidence generation – building an end-to-end platform that integrates what patients say and what their bodies show." This powerful integration means that not only will patient-reported outcomes be included, but they will be merged with real-time sensor data to build robust efficacy cases.

Enhancing Clinical Trials Through Integrated Solutions

With the combined expertise of Signant and Ametris, the new platform will bring together patient feedback on their wellbeing and performance with objective measurements derived from wearable technology. Ametris has spent two decades creating regulatory-aligned measures, capturing data from patients in their natural environments. By integrating Signant's experience in clinical outcome assessments with Ametris' innovations in sensor-based data collection, a uniquely comprehensive evidence generation approach is created.

Jeremy Wyatt, CEO of Ametris, commented on the merger, stating, "Joining Signant allows us to accelerate our vision of truly integrated multimodal evidence generation. Our combined expertise creates something unique in the industry – a single partner committed to building purpose-designed integration." This testament to collaborative innovation illustrates the potential for significant advancements in trial monitoring and patient outcomes.

Looking Ahead: The Future of Clinical Evidence Generation

As both companies move forward, they plan to maintain Ametris' innovative roadmap while significantly investing in platform integration capabilities. Short-term goals focus on creating unified data flows and streamlined workflows that enable coordinated deployment tools and integrated analytical capabilities.

The merger also unlocks the opportunity to harness advanced technologies, such as Artificial Intelligence (AI) and machine learning. These tools could lead to the identification of patterns across various data types, enhancing the potential for novel digital and composite outcome measures. The objective is to provide clinical trial sponsors with real-time insights that may transform their monitoring processes, thereby significantly improving the efficacy of their programs.

As the clinical trial landscape continues to demand more integrated and comprehensive evidence generation, the partnership between Signant Health and Ametris represents a timely and strategic opportunity to meet these evolving needs. Researchers and sponsors alike stand to benefit from the capabilities that this new entity will offer as it aims to simplify patient engagement in trials while fostering innovation in therapeutic development.

For more insights into this merger and its impact on clinical trials, visit Signant Health and Ametris.